Lakefront Biotherapeutics (LKFT) Short term Debt (2019 - 2025)

Lakefront Biotherapeutics (LKFT) has reported Short term Debt for 6 consecutive years, with $5689.8 the latest figure, recorded in Q4 2025.

• Quarterly Short term Debt changed 0.0% year-over-year to $5689.8 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $5689.8 (changed 0.0% YoY) and the FY2025 annual result came in at $5689.8, changed 0.0% from the prior year.
• Short term Debt steadied at $5689.8 in Q4 2025 per LKFT's latest filing, from $5689.8 in the prior quarter.
• Over the last five years, Short term Debt for LKFT reached as high as $442664.2 in Q1 2022 and fell as low as $5689.8 in Q4 2024.
• A 4-year average of $213707.8 and a median of $232142.7 in 2021 frame the typical range for Short term Debt.
• Annual changes were most pronounced in 2021 — Short term Debt plunged 98.77% — and 2025, when it changed 0.0%.
• Year by year, Short term Debt stood at $232142.7 in 2021, then jumped by 90.69% to $442664.2 in 2022, then tumbled by 98.71% to $5689.8 in 2024, then changed by 0.0% to $5689.8 in 2025.
• According to Business Quant data, Short term Debt over the past three periods registered $5689.8, $5689.8, and $442664.2 for Q4 2025, Q4 2024, and Q1 2022 respectively.